Global Onychomycosis Drug Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Onychomycosis Drug Market Size

• The global onychomycosis drug market was valued at USD 4.17 billion in 2024 and is projected to reach USD 6.07 billion by 2032, growing at a CAGR of 4.7% during the forecast period
• This growth is driven by factors such as increasing prevalence of fungal nail infections, rising geriatric population, greater awareness regarding personal hygiene, and growing adoption of both oral and topical antifungal therapies

Onychomycosis Drug Market Analysis

• Onychomycosis, a common fungal infection of the toenails or fingernails, leads to nail discoloration, thickening, and separation from the nail bed. It is primarily caused by dermatophytes, yeasts (like Candida), and non-dermatophyte molds
• The rising global burden of diabetes, peripheral vascular diseases, and immunosuppressive conditions has led to a higher incidence of onychomycosis, thereby fueling demand for effective pharmacological treatments
• Topical and oral antifungal drugs such as terbinafine, ciclopirox, griseofulvin, and ketoconazole are commonly used, with oral treatments offering higher cure rates but greater risk of systemic side effects
• North America holds a significant share of the market due to high disease awareness, availability of advanced treatment options, and favorable reimbursement policies
• Asia-Pacific is expected to witness the fastest growth during the forecast period, driven by a large patient pool, improving access to healthcare, and growing consumer preference for dermatological treatments
• The Distal Subungual Onychomycosis segment expected to dominate the market with 35.55% shares. This dominance is attributed to its high prevalence among all age groups and its recognizable clinical features, making diagnosis and treatment more accessible. The segment's growth is further supported by increased awareness and availability of targeted therapies.

Report Scope and Onychomycosis Drug Market Segmentation

Onychomycosis Drug Market Trends

“Advancements in Antifungal Treatments & Targeted Drug Delivery”

• One prominent trend in the onychomycosis drug market is the increasing development of advanced antifungal treatments and targeted drug delivery systems
• These innovations are enhancing the effectiveness of treatments by providing more precise and localized action, reducing systemic side effects, and improving patient compliance

• For instance, novel topical drug formulations with better penetration and sustained release mechanisms are being developed to improve efficacy for difficult-to-treat onychomycosis cases, particularly for distal subungual onychomycosis.

• These advancements are improving treatment outcomes and driving the demand for next-generation onychomycosis drugs with higher cure rates and fewer side effects

Onychomycosis Drug Market Dynamics

Driver

“Rising Incidence of Onychomycosis Due to Increased Prevalence of Diabetes and Aging Population”

• The increasing prevalence of diabetes, peripheral vascular diseases, and the aging population is contributing significantly to the rising incidence of onychomycosis, thereby boosting the demand for onychomycosis drugs
• Older adults, who are more prone to conditions such as diabetes and compromised immune systems, are at higher risk of developing fungal infections, particularly in toenails and fingernails
• As the global population ages, the demand for antifungal treatments is expected to continue growing, as more individuals require effective drugs for managing onychomycosis

For instance,

• According to a report published by the American Diabetes Association in 2022, approximately 463 million adults worldwide were living with diabetes, a condition that significantly increases the risk of fungal infections, including onychomycosis

• This rise in disease prevalence is creating a larger patient pool and driving the demand for new and improved treatments

Opportunity

“Expanding Market for Over-the-Counter (OTC) Antifungal Medications”

• The increasing availability of over-the-counter (OTC) antifungal medications presents a significant opportunity for growth in the onychomycosis drug market
• As more patients seek convenient and affordable solutions for managing mild to moderate onychomycosis, the demand for OTC drugs, including topical antifungal creams, lacquers, and sprays, is expected to rise
• Additionally, the ability of these medications to be used without prescription, coupled with consumer awareness campaigns, is driving market penetration

For instance,

• In 2023, Pfizer Inc. launched a new OTC antifungal product aimed at treating mild onychomycosis, which has seen strong consumer adoption in North America and Europe

• This trend is expected to expand in emerging markets, where OTC antifungal treatments can help increase accessibility to essential care for a larger portion of the population.

Restraint/Challenge

“High Cost of Treatment and Lack of Access in Developing Regions”

• The high cost of prescription treatments, especially oral antifungal drugs like terbinafine, poses a significant challenge to market growth, particularly in developing regions.
• Oral treatments, which offer higher efficacy for treating onychomycosis, can be expensive, limiting access for patients in lower-income regions or healthcare systems with limited resources.
• Additionally, some of the newer and more effective treatment options, such as combination therapies, are still prohibitively priced for many patients and healthcare facilities

For instance,

• In sub-Saharan Africa and parts of Asia, the availability of effective treatments remains limited due to high costs and a lack of infrastructure for widespread diagnosis and treatment.

• Consequently, this cost barrier can lead to untreated or improperly treated cases, resulting in prolonged infections, complications, and increased healthcare costs in the long term, hindering the overall market growth

Onychomycosis Drug Market Scope

The market is segmented on the basis types, drugs, treatment, route of administration, end user, and distribution channel.

In 2025, the distal subungual onychomycosis is projected to dominate the market with the largest share in the type segment

The distal subungual onychomycosis segment is expected to dominate the global onychomycosis drug market with the largest share of 39.45% in 2025 due to its widespread prevalence and easier clinical diagnosis. This type of infection is the most common form of onychomycosis, particularly affecting toenails, and often seen among diabetic and elderly patients. Increased awareness, improved access to treatment, and rising demand for effective antifungal therapies are driving the dominance of this segment.

The oral antifungal drugs segment is expected to account for the largest share during the forecast period in the drug type market

In 2025, the oral antifungal drugs segment is expected to dominate the market with the largest market share of 48.67% due to their higher efficacy in treating severe and deep nail infections compared to topical treatments. Drugs such as terbinafine and itraconazole are widely prescribed and have shown superior cure rates. The rising incidence of chronic onychomycosis and a preference for systemic treatments that provide faster and more comprehensive results are key factors driving this segment’s growth.

Onychomycosis Drug Market Regional Analysis

“North America Holds the Largest Share in the Onychomycosis Drug Market”

• North America dominates the global onychomycosis drug market, attributed to its advanced healthcare infrastructure, high awareness regarding fungal infections, and widespread access to prescription medications
• The U.S. holds a major share due to the increasing prevalence of onychomycosis among the aging population, diabetic patients, and individuals with weakened immune systems
• Favorable reimbursement policies, availability of FDA-approved antifungal therapies, and strong presence of pharmaceutical companies contribute significantly to regional market strength
• Additionally, heightened focus on personal hygiene, growing cosmetic concerns regarding nail appearance, and the presence of well-established retail and online pharmacy networks further support market expansion in the region

“Asia-Pacific is Projected to Register the Highest CAGR in the Onychomycosis Drug Market”

• The Asia-Pacific region is expected to exhibit the highest growth rate in the global onychomycosis drug market, propelled by growing awareness about fungal infections and increasing healthcare access
• Countries like China, India, and Japan are witnessing a surge in cases due to rising prevalence of diabetes, humid climates conducive to fungal growth, and increasing adoption of western lifestyle and footwear habits
• Japan, with its robust pharmaceutical industry and well-informed patient base, remains a significant contributor to market demand for advanced antifungal treatments
• In China and India, expanding middle-class populations, increasing dermatology consultations, and higher healthcare investments are driving demand for effective oral and topical antifungal drugs. The entry of global drug manufacturers and regional clinical trial activities are further accelerating market growth in the region

Onychomycosis Drug Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

The Major Market Leaders Operating in the Market Are:

• Bayer AG (Germany)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Novartis AG (Switzerland)
• AstraZeneca (UK)
• Pfizer Inc. (U.S.)
• Sanofi (France)
• Johnson & Johnson Services, Inc. (U.S.)
• AbbVie Inc. (U.S.)
• Allergan (Ireland)
• Merck & Co., Inc. (U.S.)
• Amgen Inc. (U.S.)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Takeda Pharmaceutical Company Limited (Japan)
• GlaxoSmithKline plc (UK)
• Lupin Pharmaceuticals, Inc. (India)
• Eli Lilly and Company (U.S.)
• Bristol-Myers Squibb Company (U.S.)
• Bausch Health Companies Inc. (Canada)
• GALDERMA (Switzerland)
• Moberg Pharma AB (Sweden)

Latest Developments in Global Onychomycosis Drug Market

• In February 2024, Allderma AB introduced the Terclara brand for the sale of MOB-015, effective in the treatment of onychomycosis across the European region.
• In December 2021, Bausch Health Companies Inc. revealed that JUBLIA (efinaconazole) Topical Solution, 10%, a remedy for onychomycosis, was awarded the American Podiatric Medical Association (APMA) Seal of Approval as it enhances foot health.
• In February 2021, Lupin Limited was granted approval by the US Food and Drug Administration for its Tavaborole Topical Solution indicated for onychomycosis. 

SKU-45051